Skip to main content

Table 1 Demographics of patients with relapsing primary central nervous system lymphoma

From: Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease

Number: 37
Variables
Median age in years at diagnosis (Min, Max) 63.7 (27.6, 80.1)
Gender (N, % Female) 21 (57%)
Median KPS at diagnosis (Min, Max) 80 (20, 100)
Ocular involvement (%) 7 (18.9%)
Treatment regiment HD-MTX/BBBD without rituximab: 30 (81.1%)
HD-MTX/BBBD with rituximab: 7 (18.9%)
Median age in years at relapse (Min, Max) 65.1 (31.6, 80.8)
Median time to progression in months 17.8 (95% CI 11.7–41.7)
  1. KPS Karnofsky Performance status [55], HD-MTX/BBBD High dose methotrexate with blood–brain barrier disruption